ES2913236T3 - Politerapia para tratar el cáncer con un poxvirus recombinante que expresa un antígeno tumoral y un antagonista o agonista de molécula del punto de control inmunitario - Google Patents

Politerapia para tratar el cáncer con un poxvirus recombinante que expresa un antígeno tumoral y un antagonista o agonista de molécula del punto de control inmunitario Download PDF

Info

Publication number
ES2913236T3
ES2913236T3 ES15733563T ES15733563T ES2913236T3 ES 2913236 T3 ES2913236 T3 ES 2913236T3 ES 15733563 T ES15733563 T ES 15733563T ES 15733563 T ES15733563 T ES 15733563T ES 2913236 T3 ES2913236 T3 ES 2913236T3
Authority
ES
Spain
Prior art keywords
antagonist
mva
cancer
immune checkpoint
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15733563T
Other languages
English (en)
Spanish (es)
Inventor
Susan Foy
Stefanie Mandl
Ryan Rountree
Alex Franzusoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bavarian Nordic AS
Original Assignee
Bavarian Nordic AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic AS filed Critical Bavarian Nordic AS
Application granted granted Critical
Publication of ES2913236T3 publication Critical patent/ES2913236T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ES15733563T 2014-05-13 2015-05-08 Politerapia para tratar el cáncer con un poxvirus recombinante que expresa un antígeno tumoral y un antagonista o agonista de molécula del punto de control inmunitario Active ES2913236T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461992788P 2014-05-13 2014-05-13
PCT/US2015/029855 WO2015175334A2 (en) 2014-05-13 2015-05-08 Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist

Publications (1)

Publication Number Publication Date
ES2913236T3 true ES2913236T3 (es) 2022-06-01

Family

ID=53499070

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15733563T Active ES2913236T3 (es) 2014-05-13 2015-05-08 Politerapia para tratar el cáncer con un poxvirus recombinante que expresa un antígeno tumoral y un antagonista o agonista de molécula del punto de control inmunitario

Country Status (13)

Country Link
US (1) US20170266270A1 (enExample)
EP (1) EP3142690B1 (enExample)
JP (1) JP6747981B2 (enExample)
KR (1) KR102499737B1 (enExample)
CN (1) CN106456747A (enExample)
AU (1) AU2015259510B2 (enExample)
CA (1) CA2946418C (enExample)
DK (1) DK3142690T3 (enExample)
ES (1) ES2913236T3 (enExample)
IL (1) IL248507B (enExample)
NZ (1) NZ725459A (enExample)
RU (1) RU2724433C2 (enExample)
WO (1) WO2015175334A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
JP6843736B2 (ja) * 2014-07-16 2021-03-17 トランジェーヌＴｒａｎｓｇｅｎｅ 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ
WO2016128542A1 (en) * 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016144564A2 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CN107847534B (zh) 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
EP3322732A2 (en) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
IL261321B2 (en) 2016-02-25 2023-12-01 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors
SG11201807051VA (en) 2016-02-25 2018-09-27 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
JP2019508044A (ja) * 2016-03-18 2019-03-28 ナントセル，インコーポレイテッド 樹状細胞感染のための多モードベクター
EP3225253A1 (en) * 2016-04-01 2017-10-04 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
CN107281474A (zh) * 2016-04-11 2017-10-24 中国科学院上海巴斯德研究所 增强抗肿瘤免疫反应的新型免疫策略和免疫组合物
CA3026172A1 (en) 2016-06-02 2017-12-07 Ultimovacs As A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
TWI781120B (zh) * 2016-11-02 2022-10-21 美商永斯醫療股份有限公司 Ｐｄ-１之抗體及其用途
KR200486872Y1 (ko) 2016-11-16 2018-07-10 김영선 가변형 조립식 책상
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
KR102684237B1 (ko) 2017-06-21 2024-07-11 트랜스진 개인 맞춤형 백신
JP7202362B2 (ja) * 2017-08-24 2023-01-11 バヴァリアン・ノルディック・アクティーゼルスカブ 組み換えｍｖａ及び抗体の静脈内投与を用いた、がん治療のための併用療法
US20210177964A1 (en) * 2017-11-06 2021-06-17 Memorial Sloan Kettering Cancer Center Heat-inactivated vaccinia virus as a vaccine immune adjuvant
US20190367568A1 (en) * 2018-02-05 2019-12-05 Nantbio, Inc. Calreticulin and fusion proteins
TWI787500B (zh) * 2018-04-23 2022-12-21 美商南特細胞公司 新抗原表位疫苗及免疫刺激組合物及方法
US11564980B2 (en) 2018-04-23 2023-01-31 Nantcell, Inc. Tumor treatment method with an individualized peptide vaccine
CN116162654A (zh) 2018-09-15 2023-05-26 纪念斯隆凯特琳癌症中心 用于癌症免疫疗法的重组痘病毒
BR112021009856A8 (pt) 2018-11-20 2021-09-08 Bavarian Nordic As Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US20220152168A1 (en) * 2019-03-20 2022-05-19 Children's Hospital Of Eastern Ontario Research Institute Inc. Sequential heterologous boost oncolytic viral immunotherapy
JP7732977B2 (ja) 2019-09-20 2025-09-02 トランスジーン Ｈｐｖポリペプチドおよびｉｌ－２をコードするポックスウイルスと抗ｐｄ－ｌ１抗体の組合せ
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
CN114929268A (zh) * 2019-11-20 2022-08-19 巴法里安诺迪克有限公司 4-1bbl辅助的重组修饰的安卡拉痘苗病毒(mva)的医疗用途
BR112022009798A2 (pt) * 2019-11-20 2022-10-18 Bavarian Nordic As Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1119354A (en) * 1914-01-05 1914-12-01 Adelbert Armstrong Broom-holder.
US1391972A (en) * 1920-08-05 1921-09-27 American Cotton Oil Company Method and apparatus for molding soap
CN109485727A (zh) * 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法

Also Published As

Publication number Publication date
JP2017515837A (ja) 2017-06-15
CN106456747A (zh) 2017-02-22
EP3142690A2 (en) 2017-03-22
KR102499737B1 (ko) 2023-02-13
AU2015259510B2 (en) 2020-10-01
RU2016148311A (ru) 2018-06-18
IL248507B (en) 2022-07-01
WO2015175334A2 (en) 2015-11-19
JP6747981B2 (ja) 2020-08-26
CA2946418A1 (en) 2015-11-19
KR20170003556A (ko) 2017-01-09
DK3142690T3 (da) 2022-05-09
RU2016148311A3 (enExample) 2018-12-26
US20170266270A1 (en) 2017-09-21
NZ725459A (en) 2023-04-28
CA2946418C (en) 2023-07-04
EP3142690B1 (en) 2022-02-23
AU2015259510A1 (en) 2016-11-10
IL248507A0 (en) 2016-12-29
WO2015175334A3 (en) 2016-02-04
RU2724433C2 (ru) 2020-06-23

Similar Documents

Publication Publication Date Title
ES2913236T3 (es) Politerapia para tratar el cáncer con un poxvirus recombinante que expresa un antígeno tumoral y un antagonista o agonista de molécula del punto de control inmunitario
JP7368305B2 (ja) 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法
US20210205429A1 (en) Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of an Immune Checkpoint Inhibitor
AU2014347004A1 (en) Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor
US20170106065A1 (en) Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
US20150283220A1 (en) Methods and compositions for the treatment of cancer
NZ725519B2 (en) Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3